Daily Stock List
Vycor Medical, Inc. (VYCO)
Wall Street Resources reported this week on Vycor Medical, Inc. (VYCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Vycor Medical, Inc. is a provider of innovative and first-class surgical and therapeutic solutions. The Company operates two business units. These are Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has its corporate headquarters in Boca Raton, Florida.
Vycor Medical has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, and Japan. The Company is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam.
The Company’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for faster, safer, and more economical brain surgeries and a quicker patient discharge. The design of VBAS is to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community.
The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. These help improve and partially restore sight in patients with neurological vision impairments. Its proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries.
VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss. Moreover, VRT has CE Marking for the EU. Additionally, NovaVision provides Neuro Eye Therapy (NeET) in the EU, targeted at increasing visual sensitivity deep within the field defect. The Company has also developed NeuroEyeCoach™. This is a therapy which is highly complementary to VRT™.
This week, Vycor Medical announced that it entered into an agreement with HealthSouth Corporation (HLS) to make available its NeuroEyeCoach Professional Center therapy program to participating HealthSouth hospitals, following a three-month trial of the therapy in two HealthSouth locations. HealthSouth is one of the largest providers of post-acute healthcare services in the United States.
NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder because of a stroke or brain injury. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently.
Vycor Medical, Inc. (VYCO), closed Friday's trading session at $1.59, up 1.27%, on 8,200 volume with 11 trades. The average volume for the last 60 days is 12,918 and the stock's 52-week low/high is $1.26/$3.12.
Vaccinogen, Inc. (VGEN)
Wyatt Investment Research, InvestorPlace, RedChip, and Zacks reported earlier on Vaccinogen, Inc. (VGEN), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2007, Vaccinogen, Inc. is a cancer immunotherapy development company. It is clinically testing OncoVAX®, a treatment designed to prevent the recurrence of colon cancer and potentially other solid tumors. This is a patented process that leverages a patient's own live tumor cells to launch an extensive immune response against minimal residual disease. Vaccinogen is based in Baltimore, Maryland and the Company’s shares trade on the OTC Markets’ OTCQB.
Vaccinogen’s belief is that OncoVAX®, at an optimum dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence following surgical resection through addressing the diversity of cancer cells inherent to each patient's tumor. Five clinical studies of OncoVAX® have been completed to date. This includes a Phase III trial with the optimum dose and regimen.
Vaccinogen expects to begin enrolling patients in a pivotal Phase IIIb trial under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA) with the FDA within 60 days of obtaining adequate funding. The Company has the manufacturing capability to produce OncoVAX® for its pivotal Phase IIIb trial. It also has a strong novel patent portfolio to protect it and its other platforms.
Vaccinogen has developed other programs in active specific immunotherapy (vaccines) and passive specific immunotherapy (fully human monoclonal antibodies). Additionally, the Company is concentrating on discovering, developing, and manufacturing fully human monoclonal antibodies for human clinical use. Its HumaSPECT antibody was one of the first to be widely approved for any clinical use worldwide.
Vaccinogen announced earlier the closing of the second $10 million tranche of the $80 million financing announced in August 2014. The capital will be used to fund further Company expansion and ACTIVE, a confirmatory Phase IIIb study of OncoVAX®. The second tranche brings the total amount closed to $20 million of the $80 million committed at $5.50 per share or unit.
In May, Vaccinogen announced that its Board of Directors unanimously elected Co-founder, President, Chief Executive Officer and current Director, Mr. Andrew L. Tussing, to the role of Chairman of the Board. Mr. Tussing replaces Mr. Benjamin S. Carson, Sr., MD. Mr. Carson resigned from the Board and his role as Chairman and a member of Vaccinogen's Medical Advisory Board role to pursue his candidacy for the President of the United States through the Republican nomination.
Vaccinogen, Inc. (VGEN), closed Friday's trading session at $2.24, up 22.40%, on 33,590 volume with 38 trades. The average volume for the last 60 days is 7,749 and the stock's 52-week low/high is $1.65/$5.00.
GenSpera, Inc. (GNSZ)
SmallCapVoice, FeedBlitz, and Standout Stocks reported on GenSpera, Inc. (GNSZ), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
GenSpera, Inc. is a biotechnology company that lists on the OTC Markets’ Group’s OTCQB. The Company conceives, designs, and develops cancer therapies. Its technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for the targeted release of drug candidates within tumors. GenSpera has its corporate headquarters in San Antonio, Texas.
GenSpera’s Scientific Advisory Board consists of leading researchers who are both the inventors of the technology and shareholders. The Company’s technology platform supports the development of a group of drugs targeted at different cancers, and also other applications such as imaging.
GenSpera’s lead drug candidate is mipsagargin. It was granted Orphan Drug designation by the US Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer). Phase II clinical trials for lead compound mipsagargin, also known as G-202, are underway in two indications. One is the above-mentioned liver cancer and the other is glioblastoma, or brain cancer.
GenSpera announced in January 2015 the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results were presented on January 16, 2015 (Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA) that is highly expressed in tumor vasculature and prostate cancer cells.
The Phase II results demonstrated that mipsagargin appears to be effective and is well-tolerated by HCC patients. The Phase II study results (n=25) demonstrate that the prodrug effectively stabilizes progression of HCC by reducing blood flow within tumors while not affecting blood flow within normal tissues.
Recently, GenSpera announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,957,016. This patent expands the Company’s Intellectual Property (IP) portfolio claiming many compositions for its prodrugs designed to be activated by Prostate Specific Antigen (PSA).
Furthermore, GenSpera also recently announced that the patent application "Injectable Cancer Compositions" entered the national phase application process in 17 countries and regions. This includes Europe, Eurasia, Japan, China, Brazil and the U.S. When awarded, the resulting patent application will extend the exclusivity period for the Company’s core IP around its entire platform technology, including its lead drug candidate, mipsagargin, until 2033.
In May, GenSpera announced the successful completion of the first stage of an ongoing Phase II study of its lead investigational agent, mipsagargin (G-202), in glioblastoma (brain cancer) and the continuation of enrollment for an expansion phase of the trial. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, California. The study will evaluate the efficacy, safety, as well as central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma.
GenSpera, Inc. (GNSZ), closed Friday's trading session at $0.78, up 5.41%, on 62,968 volume with 46 trades. The average volume for the last 60 days is 21,834 and the stock's 52-week low/high is $0.48/$1.07.
Integral Technologies, Inc. (ITKG)
SmallCapVoice and Wall Street Resources reported on Integral Technologies, Inc. (ITKG), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
OTCQB-listed Integral Technologies, Inc. is a developing leader in hybrid conductive plastics. The Company and its wholly-owned subsidiary, ElectriPlast Corp., engage in the discovery, development, and commercialization of electrically conductive hybrid plastics used chiefly as raw materials in the production of industrial, commercial, and consumer products and services globally. Integral Technologies’ primary product line is ElectriPlast™ with Flexible Content Technology™. The Company has an extensive Intellectual Property (IP) portfolio referencing its ElectriPlast technology. Integral Technologies has its headquarters in Canton, Michigan.
ElectriPlast™ with Flexible Content Technology™ is a family of non-corrosive, electrically-conductive resin-based materials. Its properties allow it to be molded into any of the innumerable shapes and sizes associated with plastics, rubbers, and other polymers while reducing component weight by 40 percent to 60 percent.
Applications for ElectriPlast include Shielding Wire, Power Electronics, Connectors, and Cables; Shielding, Conduction, Batteries, and Semiconductors. Applications additionally include Heated Elements, Sensors, Antennas, Medical Devices, Consumer Electronics and Acoustics, Fuses, Capacitors, Resistors, RFID, Busbars and Terminals.
Integral Technologies and Hanwha L&C earlier signed a 10-year agreement. This agreement grants Hanwha L&C an exclusive right to sell, distribute, and manufacture ElectriPlast in South Korea. Hanwha also acquired non-exclusive sales and distribution rights to ElectriPlast in Japan, Taiwan, and China. Hanwha L&C is part of the Hanwha Group of companies that together form one of the largest conglomerates in South Korea.
Integral Technologies and ElectriPlast earlier announced the modification of its license agreement dated June 21, 2013, with Hanwha Advanced Materials, formerly Hanwha L&C, because of the sale of certain non-automotive related assets. This includes its previous name Hanwha L&C, to Morgan Stanley Private Equity.
Last month, Integral Technologies’ wholly-owned subsidiary ElectriPlast announced the Company's invention of a patent pending, highly conductive plastic bipolar plate that will undergo development into a lightweight, mouldable and cost effective battery. This is an additional example of ElectriPlast's lightweighting benefits available to serve a new market vertical: batteries and power storage. The ElectriPlast bipolar plate also provides further benefits to manufacturers and end users; it reduces steps and time in the manufacturing process, provides flexibility in the form factor of the battery, and is environmentally friendly.
Integral Technologies, Inc. (ITKG), closed Friday's trading session at $0.69, up 7.71%, on 91,539 volume with 68 trades. The average volume for the last 60 days is 184,132 and the stock's 52-week low/high is $0.2581/$0.85.
Santa Fe Gold Corp. (SFEG)
TheMicrocapNews and SmarTrend Newsletters reported on Santa Fe Gold Corp. (SFEG), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.
Santa Fe Gold Corp. is a U.S. mining company based in Albuquerque, New Mexico. It has a general business strategy to acquire and develop mining properties amenable to low cost production. Santa Fe controls the Summit mine and Lordsburg mill in southwestern New Mexico; a significant land position near the Lordsburg mill, consisting of the core of the Lordsburg Mining District; and a deposit of micaceous iron oxide (MIO) in Western Arizona. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Santa Fe Gold’s intention is to build a portfolio of high-quality, diversified mineral assets with an emphasis on precious metals. Its projects include Summit Gold-Silver, Mogollon Gold-Silver, Ortiz Gold, Black Canyon Mica, and Planet Micaceous Iron Oxide. In April 2012, the Summit silver-gold project attained commercial production.
In November 2013 operations were temporarily suspended pending attainment of new financing to properly capitalize mine expansion. In addition, Santa Fe Gold’s intention is to advance the Mogollon and Ortiz gold projects.
In January of this year, Santa Fe Gold announced that it staked and filed mineral claims covering an approximate nine square mile area immediately next door to its patented claims position covering most of the historic Lordsburg Mining District. The Company’s land position at Lordsburg now totals around13 square miles. Santa Fe Gold also unveiled its porphyry and high-grade vein copper strategy. Furthermore, it announced the appointment of Mr. James Baughman as its Senior Vice President & Chief Geologist.
In addition, in March, Santa Fe Gold announce that it staked and filed an additional 88 mineral claims immediately next to its patented and unpatented claims position covering most of the historic Lordsburg Mining District. Additionally, the Company announced that it renewed a strategic lease covering 13 patented and six unpatented claims in the Lordsburg District.
In March, Mr. Jakes Jordaan, Santa Fe Gold’s President & Chief Executive Officer said, “We are excited to have completed our staking targets and finalized most of our strategic leasing objectives in the Lordsburg district. In addition, we have nearly completed our strategic partner selection process. We are most encouraged by strategic proposals from both strategic and financial participants with respect to our Lordsburg porphyry copper strategic objectives.
Santa Fe Gold Corp. (SFEG), closed Friday's trading session at $0.0699, up 39.80%, on 484,262 volume with 52 trades. The average volume for the last 60 days is 100,882 and the stock's 52-week low/high is $0.0216/$0.2895.
Pure Hospitality Solutions, Inc. (PNOW)
The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.0021, up 5.00%, on 7,593,870 volume with 79 trades. The stock’s average daily volume over the past 60 days is 4,251,128, and its 52-week low/high is $0.0013/$0.5882.
Pure Hospitality Solutions, Inc. announced today, that the Company continues to grow its database, teaming up with the Jaco Tour Company [Costa-Rican]; officially adding excursions to Oveedia's Travel Network. PURE's growing relationship with properties like Tango Mar and now expedition companies like Jaco Tour Company, greatly increases the viability of Oveedia's upcoming pre-launch test (Alpha & Beta).
Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.
The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.
Operating a successful bi-lateral business model, Pure has four objectives:
1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;
2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;
3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,
4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.
The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.
Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer
Pure Hospitality Solutions, Inc. Company Blog
Pure Hospitality Solutions, Inc. News:
PURE Hospitality Solutions Teams Up With Jaco Tour Company
PURE Hospitality Solutions Accelerates Debt Reduction Program
PURE Hospitality Solutions Submits Oveedia Architecture to Sabre
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.107, up 7.11%, on 92,819 volume with 19 trades. The stock’s average daily volume over the past 60 days is 73,501, and its 52-week low/high is $0.0114/$1.01.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial $2.5 Million Sea Otter Global Ventures Financing Progresses
IFAN Financial Announces $2.5 Million Financing by Sea Otter Global Ventures, LLC
IFAN Financial Applauds Facebook's Move Into the Mobile Payments Industry, Foresees Ancillary Opportunities
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, even for the day. The stock’s average daily volume over the past 60 days is 445, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.0462, off by 2.74%, on 70,904 volume with 12 trades. The stock’s average daily volume over the past 60 days is 782,482, and its 52-week low/high is $0.045/$0.15.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting
International Stem Cell Corporation Announces 2015 First Quarter Results
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Save The World Air, Inc. (ZERO)
The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.35, off by 6.37%, on 110,550 volume with 23 trades. The stock’s average daily volume over the past 60 days is 106,133, and its 52-week low/high is $0.3401/$0.839.
Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.
In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.
The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.
STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.
Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer
Save The World Air, Inc. Company Blog
Save The World Air, Inc. News:
STWA Deploys Joule Heat Direct Heating System on Gathering Line for Crude Oil Pipeline in Uintah Basin
STWA Congratulates Pipeline Research Council International on New Technology Development Center
STWA Announces Preliminary AOT(TM) Test Results From Southern Research Institute
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Subsidiary Signs Agreement With Edmonton International Airport
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Energy Signs Multi-Megawatt Agreement
- Galenfeha, Inc. (GLFH) Completes Field Testing, Begins Production and Shipping of New Battery System
- Growblox Sciences, Inc. (GBLX) Announces Commercialization Initiative and Financing
- IFAN Financial, Inc. (IFAN) $2.5 Million Sea Otter Global Ventures Financing Progresses
- International Stem Cell Corp. (ISCO) to Present at International Society for Cellular Therapy Annual Meeting
- Loans4Less.com Inc. (LFLS) Enters into an Acquisition Agreement with 321LEND
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) Raises Capital to Fund National Expansion and Convertible Note Elimination
- Pure Hospitality Solutions, Inc. (PNOW) Teams Up With Jaco Tour Company
- Save The World Air, Inc. (ZERO) Deploys Joule Heat Direct Heating System on Gathering Line for Crude Oil Pipeline in Uintah Basin
- View Systems, Inc. (VSYM) Continues to Install Its Proprietary Scanning Systems Nationwide
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors